Shanetta D Ore

Array ( [id] => 13837223 [patent_doc_number] => 20190022096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/945677 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15945677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490223 [patent_doc_number] => 20180296654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 15/944072 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15944072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496471 [patent_doc_number] => 11285154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Methods and compositions for treating cancer [patent_app_type] => utility [patent_app_number] => 15/940802 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 139 [patent_no_of_words] => 16485 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15940802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806187 [patent_doc_number] => 20210128740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 16/492355 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13329057 [patent_doc_number] => 20180216066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => METHODS FOR ISOLATING AND PROLIFERATING AUTOLOGOUS CANCER ANTIGEN-SPECIFIC CD8+ T CELLS [patent_app_type] => utility [patent_app_number] => 15/936209 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15936209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425181 [patent_doc_number] => 20180264133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => LINKER UNITS AND MOLECULAR CONSTRUCTS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 15/922935 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 361 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15922935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300293 [patent_doc_number] => 20180201683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => CELL LINE 3M [patent_app_type] => utility [patent_app_number] => 15/913445 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483997 [patent_doc_number] => 20200377598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => Induction and Enhancement of Antitumor Immunity Involving Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens and Immune Checkpoint Inhibitors or Proteins [patent_app_type] => utility [patent_app_number] => 16/489769 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887720 [patent_doc_number] => 11866481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => TGF-b-receptor ectodomain fusion molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 16/490335 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 11484 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14452491 [patent_doc_number] => 10322192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => Eribulin-based antibody-drug conjugates and methods of use [patent_app_type] => utility [patent_app_number] => 15/892921 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 31 [patent_no_of_words] => 58769 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15892921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790765 [patent_doc_number] => 20180155424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => Compositions and Methods to Enhance the Immune System [patent_app_type] => utility [patent_app_number] => 15/890138 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786526 [patent_doc_number] => 20180154011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => SELF-STABILIZING LINKER CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/890252 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13325981 [patent_doc_number] => 20180214528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => PHARMACEUTICAL COMPOSITION FOR INHIBITING EXPRESSION OF CD47 IN TUMOR CELLS AND USE OF SAME [patent_app_type] => utility [patent_app_number] => 15/881452 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452610 [patent_doc_number] => 20200362036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => NOVEL COMBINATION AND USE OF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/959425 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702370 [patent_doc_number] => 20180125956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER [patent_app_type] => utility [patent_app_number] => 15/866896 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19146 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16518683 [patent_doc_number] => 10869885 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Tumor lysate loaded particles [patent_app_type] => utility [patent_app_number] => 15/864496 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 6542 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383793 [patent_doc_number] => 20180243438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/854742 [patent_app_country] => US [patent_app_date] => 2017-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15854742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535351 [patent_doc_number] => 20190203297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => PHOSPHOLIPASE C GAMMA 2 AND RESISTANCE ASSOCIATED MUTATIONS [patent_app_type] => utility [patent_app_number] => 15/844751 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681040 [patent_doc_number] => 20180118846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => DISEASE THERAPY BY INDUCING IMMUNE RESPONSE TO TROP-2 EXPRESSING CELLS [patent_app_type] => utility [patent_app_number] => 15/843252 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15843252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413281 [patent_doc_number] => 20180258183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER [patent_app_type] => utility [patent_app_number] => 15/824055 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15824055 [rel_patent_id] =>[rel_patent_doc_number] =>)